The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / November / Viridian Reports Positive Phase 1 Results for VRDN008
Research & Innovations Latest News

Viridian Reports Positive Phase 1 Results for VRDN-008

Investigational therapy demonstrates sustained IgG reductions for up to eight weeks, supporting less frequent dosing for autoimmune diseases

11/18/2026 2 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll
Objective:

The article examines the objective, findings, and clinical context described in Viridian Reports Positive Phase 1 Results for VRDN-008.

Approach:
  • Study: Healthy volunteers received two subcutaneous doses of VRDN-008: at baseline and at week four.
  • Planned development: Viridian plans to begin at least one pivotal trial in 2027, starting with myasthenia gravis, subject to regulatory feedback. The proposed study will assess dosing every four and eight weeks.
Key Findings:
  • The company reported a peak IgG reduction of 74%, with suppression maintained for up to eight weeks after administration.
  • The reported drug half-life was 15–18 days, approximately six times longer than first-generation Fc fragments.
  • VRDN-008 was generally well tolerated; no serious adverse events or dose-limiting toxicities were reported.
  • Treatment did not reduce albumin or LDL cholesterol.
Interpretation:

Viridian describes VRDN-008 as a half-life-extended FcRn inhibitor intended to reduce circulating IgG. The reported Phase 1 results are from healthy volunteers; clinical benefit in autoimmune disease has not been established.

Limitations:
  • The context provides no sample size or detailed study methods.
  • VRDN-008 has not demonstrated clinical benefit in thyroid eye disease, and no TED-specific development program has been announced.
  • Further trials are needed to assess whether sustained IgG suppression translates into patient outcomes.
Conclusion:

Viridian plans to investigate VRDN-008 in myasthenia gravis and potentially other autoantibody-mediated diseases; indications beyond MG have not been specified.

Sources:
  • Viridian Therapeutics announcement, as described in the supplied context

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: